Changes in fat cells linked to diabetes
July 7th, 2010 - 4:41 pm ICT by ANIWashington, July 7 (ANI): A new research from the University of Cincinnati (UC) suggests that cellular changes in fat tissue-not the immune system-lead to the ‘hyperinflammation’ characteristic of obesity-related glucose intolerance and type 2 diabetes.
Cancer and cell biology experts say this new discovery about the cellular mechanisms behind glucose intolerance may provide a different target for drugs to treat type 2 diabetes as well as insights into how aggressive cancers form.
For this study, lead author Jorge Moscat and his UC collaborator Maria Diaz-Meco, looked at the role of a specific gene known as protein kinase C (PKC)-zeta, which has been implicated as a key cellular contributor to malignant tumor growth.
Using a preclinical animal model, they found that PKC-zeta had a dual role in the molecular signaling that leads to inflammation, switching from acting as a regulator of inflammation to a proinflammation agent in different circumstances.
“This finding is quite novel because current drug development efforts target immune cells (macrophages, T-cells) to eliminate this hyperinflammation. Our research suggests obesity-related glucose intolerance has nothing to do with the immune system. It may be more effective to target adipocytes (fat cells),” said Moscat.
In normal cells, explains Moscat, PKC-zeta regulates the balance between cellular inflammatory responses to maintain glucose control. During obesity-induced inflammation, however, the function of PKC-zeta changes and the molecule begins to promote inflammation by causing adipocytes to secrete a substance (IL-6) that travels in large quantities to the liver to cause insulin resistance.
“We believe a similar mechanism of action is at play in malignant tumor development. Now we are trying to understand how PKC-zeta regulates IL6 to better determine how we can manipulate the protein to help prevent diabetes and cancer,” he added.
Moscat and his team are working with investigators at UC’s Drug Discovery Center to screen compounds that will inhibit PKC-zeta to be used in further research.
The study is reported in the July 7, 2010, issue of the scientific journal Cell Metabolism. (ANI)
- Potential new target for diabetes, heart disease treatments identified - Nov 17, 2010
- Pancreatic cancers use fructose to fuel their growth - Aug 04, 2010
- Fructose-rich Western diets fuel growth of pancreatic cancers - Aug 12, 2010
- Novel tumour suppressor for lung cancer identified - Jan 06, 2009
- Normal healthy breast cells can help kill cancer cells - Apr 14, 2011
- Protein that contributes to ulcerative colitis revealed - Apr 02, 2011
- Decrease in protein levels could be sign child will develop diabetes - Apr 26, 2011
- Protein that fuels inflammation in pancreatic and breast tumors identified - Feb 22, 2011
- Protein that modulates metabolic dysfunction in obesity identified - Jun 18, 2010
- New discovery may help reduce obesity complications - Feb 04, 2010
- Weight loss lowers diabetics' risk of heart attacks - May 04, 2012
- Cell killer enzyme could help cancer treatment - Mar 06, 2011
- Brain insulin plays critical role in development of diabetes - Feb 17, 2011
- Micro-RNA that regulates insulin in obesity identified - Apr 01, 2011
- Salmonella could be used to fight cancer - Mar 10, 2011
Tags: animal model, cell biology, cellular changes, cellular mechanisms, fat cells, glucose control, glucose intolerance, immune cells, inflammatory responses, insulin resistance, maria diaz, moscat, new discovery, pkc zeta, protein kinase c, t cells, target, tumor development, type 2 diabetes, university of cincinnati